Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $238.6 million.

  • 10x Genomics' Total Non-Current Liabilities rose 1724.8% to $238.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $238.6 million, marking a year-over-year increase of 1724.8%. This contributed to the annual value of $238.6 million for FY2025, which is 1724.8% up from last year.
  • Latest data reveals that 10x Genomics reported Total Non-Current Liabilities of $238.6 million as of Q4 2025, which was up 1724.8% from $235.8 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Total Non-Current Liabilities peaked at $238.6 million during Q4 2025, and registered a low of $181.9 million during Q3 2021.
  • Its 5-year average for Total Non-Current Liabilities is $203.5 million, with a median of $200.8 million in 2024.
  • In the last 5 years, 10x Genomics' Total Non-Current Liabilities tumbled by 1475.46% in 2021 and then skyrocketed by 1800.97% in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' Total Non-Current Liabilities stood at $193.0 million in 2021, then grew by 14.11% to $220.3 million in 2022, then dropped by 0.2% to $219.8 million in 2023, then dropped by 7.44% to $203.5 million in 2024, then rose by 17.25% to $238.6 million in 2025.
  • Its last three reported values are $238.6 million in Q4 2025, $235.8 million for Q3 2025, and $200.6 million during Q2 2025.